Evaluation of the digital rectal examination as a screening test for prostate cancer

Journal of the National Cancer Institute

Volumn 90, Issue 23, 1998, Pages 1817-1823

  Schröder, Fritz H ^a,b   Van Der Maas, Paul ^b   Beemsterboer, Petra ^b   Kruger, Arto Boeken ^a   Hoedemaeker, Robert ^a   Rietbergen, John ^a   Kranse, Ries ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; CONTROLLED STUDY; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PHYSICAL EXAMINATION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME;

EID: 0032477329     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.23.1817     Document Type: Article

References (30)

1. American Urological Association. Executive Committee report. Baltimore (MD): American Urological Association: January 1992.
2. American Cancer Society. Guidelines for the cancer-related checkup: an update. Atlanta (GA): American Cancer Society; 1993.
3. Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343:958-60.
4. Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence - data from the Utah Cancer Registry. Cancer 1996;77:1342-8.
5. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 1994;152:1905-9.
6. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992;147:846-51; discussion 851-2.
7. Auvinen A, Rietbergen JB, Denis LJ, Schroder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996;3: 97-104.
8. Schroder FH, Damhuis RA, Kirkels WJ, De Koning HJ, Kranse R, Nus HG, et al. European randomized study of screening for prostate cancer - the Rotterdam pilot studies. Int J Cancer 1996;65:145-51.
9. Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992;148:829-32.
10. Hoedemaeker RF, Rietbergen JB, Kranse R, van der Kwast TH, Schroder FH. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol 1997;15:339-45.
11. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
12. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23: 273-9.
13. Essex-Sorlie D. Medical biostatistics and epidemiology: examination and board review. Englewood Cliffs (NJ): Prentice-Hall; 1995.
14. Daneshgari F, Taylor GD, Miller GJ, Crawford ED. Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 1995;45:604-9.
15. Jewett HJ, Bridge RW, Gray GF Jr, Shelley WM. The palpable nodule of prostatic cancer. Results 15 years after radical excision. JAMA 1968;203:403-6.
16. Bentvelsen FM, Schroder FH. Modalities available for screening for prostate cancer. Eur J Cancer 1993;29A:804-11.
17. Mueller EJ, Crain TW, Thompson IM, Rodriguez FR. An evaluation of serial digital rectal examinations in screening for prostate cancer. J Urol 1988;140:1445-7.
18. Cooner WH, Mosley BR, Rutherford CJ Jr, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;143:1146-52; discussion 1152-4.
19. Friedman GD, Hiatt RA, Quesenberry CP Jr, Sleby JV. Case-control study of screening for prostatic cancer by digital rectal examinations. Lancet 1991;337:1526-9.
20. Palken M, Cobb OE, Simons CE, Warren BH, Aldape HC. Prostate cancer: comparison of digital rectal examination and transrectal ultrasound for screening. J Urol 1991;145:86-90; discussion 90-2.
21. Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 1989;141: 1136-8.
22. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991;67:2949-58.
23. Richie JP, Catalona WJ, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 1993;42: 365-74.
24. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996;47:863-9.
25. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997;277: 1456-60.
26. De Koning HJ, Fracheboud J, Boer R, Verbeek AL, Collette HJ, Hendriks JH, et al. Nationwide breast cancer screening in The Netherlands: support for breast-cancer mortality reduction. National Evaluation Team for Breast Cancer Screening (NETB). Int J Cancer 1995; 60:777-80.
27. Beemsterboer PM, de Koning HJ, Warmerdam PG, Boer R, Swart E, Dierks ML, et al. Prediction of the effects and costs of breast-cancer screening in Germany. Int J Cancer 1994;58: 623-8.
28. Shapiro S, Venet W, Strax P, Venet L. Current results of the breast cancer screening randomized trial: the Health Insurance Plan (HIP) of Greater New York. In: Day NE, Miller AB, editors. Screening for breast cancer. Toronto (ON): H. Huber Publishers; 1988. p. 3-16.
29. van den Ouden D, Hop WC, Kranse R, Schroder FH. Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol 1997;79: 203-11.
30. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997;277:1452-5.